HIGHLIGHTS
- who: Akanksha Behl from the xorubicin (DOX), trifluoroacetate salt (, inhibitor), Rhodamine , (Rh, ), Rhodamine B (RhoB), , diamidino-2-phenylindole (DAPI), Fluorescein isothiocyanate (FITC), Coumarin-6, poly ethylene glycol, (PEG-5000), caprolactone, Tin (II), ethylhexanoate, (4, Dimethylthiazol-2-yl)-2, Diphenyltetrazolium Bromide (MTT), Dimethylsulfoxide (DMSO), Bradford reagent, chemiluminescence reagent purchased from Sigma aldrich (Merck, USA have published the research work: Biodegradable PEG-PCL Nanoparticles for Co-delivery of MUC1 Inhibitor and Doxorubicin for the Confinement of Triple-Negative Breast Cancer, in the Journal: (JOURNAL) of August/31,/2017
- what: This research reports for the first time the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.